No data on real-life experiences of risankizumab efficacy and safety are reported, apart from two isolated case reports. We carried out a single-centre, prospective study to assess the efficacy and safety of risankizumab. Fourteen patients were included (mean age 44.5 ± 14.2 years). Mean PASI decreased from 12.3 ± 5.2 (baseline) to 4.4 ± 2.7 at week 4 (p < 0.01), and to 2.7 ± 1.7 at week 16 (p < 0.001). A similar trend was observed for BSA. In patients previously treated with biologics (71.4%, n = 10) versus the naïve ones, mean baseline PASI was similar (12.7 ± 5.8 vs 11.3 ± 3.8). Mean BSA was higher in multifailure (23.5 ± 11.8 vs 15.5 ± 11.8). At 4 and 16 weeks, a significant improvement in PASI and BSA was observed in both groups. An improvement in NAPSI score, mean scalp, and palmo-plantar area reduction was noticed during follow-up. No AEs were reported up to week 16 and few and mild grade laboratory tests were reported. Our initial data confirm the promising results on efficacy and safety of Risankizumab, even in a more challenging and "real" population, composed of a high percentage of multi-failure psoriatic patients who have benefitted from a new class agent.

Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period / Megna, Matteo; Cinelli, Eleonora; Gallo, Lucia; Camela, Elisa; Ruggiero, Angelo; Fabbrocini, Gabriella. - In: ARCHIVES OF DERMATOLOGICAL RESEARCH. - ISSN 0340-3696. - 314:(2022), pp. 619-623. [10.1007/s00403-021-02200-7]

Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

Megna, Matteo
;
Cinelli, Eleonora;Gallo, Lucia;Camela, Elisa;Ruggiero, Angelo;Fabbrocini, Gabriella
2022

Abstract

No data on real-life experiences of risankizumab efficacy and safety are reported, apart from two isolated case reports. We carried out a single-centre, prospective study to assess the efficacy and safety of risankizumab. Fourteen patients were included (mean age 44.5 ± 14.2 years). Mean PASI decreased from 12.3 ± 5.2 (baseline) to 4.4 ± 2.7 at week 4 (p < 0.01), and to 2.7 ± 1.7 at week 16 (p < 0.001). A similar trend was observed for BSA. In patients previously treated with biologics (71.4%, n = 10) versus the naïve ones, mean baseline PASI was similar (12.7 ± 5.8 vs 11.3 ± 3.8). Mean BSA was higher in multifailure (23.5 ± 11.8 vs 15.5 ± 11.8). At 4 and 16 weeks, a significant improvement in PASI and BSA was observed in both groups. An improvement in NAPSI score, mean scalp, and palmo-plantar area reduction was noticed during follow-up. No AEs were reported up to week 16 and few and mild grade laboratory tests were reported. Our initial data confirm the promising results on efficacy and safety of Risankizumab, even in a more challenging and "real" population, composed of a high percentage of multi-failure psoriatic patients who have benefitted from a new class agent.
2022
Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period / Megna, Matteo; Cinelli, Eleonora; Gallo, Lucia; Camela, Elisa; Ruggiero, Angelo; Fabbrocini, Gabriella. - In: ARCHIVES OF DERMATOLOGICAL RESEARCH. - ISSN 0340-3696. - 314:(2022), pp. 619-623. [10.1007/s00403-021-02200-7]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/839238
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 39
social impact